Trends in the Prevalence and Susceptibility of ESBL-producing Entererobacteriaceae to Various Antimicrobial Agents in Russian ICUs | CMAC

Trends in the Prevalence and Susceptibility of ESBL-producing Entererobacteriaceae to Various Antimicrobial Agents in Russian ICUs

Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(4):323-336

​ Edelstein M.V., Stratchounski L.S., ROSNET study group
extended-spectrum β-lactamase Enterobacteriaceae nosocomial infections
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(4):323-336

Abstract

The prevalence of extended-spectrum β-lactamase (ESBL) production in nosocomial Enterobacteriaceae isolated in ICUs of various regions of Russia in 1997–1998 and 2003 was studied. We report the dramatic increase in the incidence of ESBLs, attributed mainly to the dissemination of the CTX-M-type β-lactamases. The results of in vitro susceptibility testing of ESBL producers indicate that the activity of non-β-lactam agents (amikacin and ciprofloxacin) significantly decreased during the time period of the study. Carbapenems and cefoperazone/sulbactam still remain the drugs of choice for the treatment of nosocomial infections caused by ESBL producers.

  • 1. Finegold S.M. In vitro efficacy of beta-lactam/ beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999; 12(Suppl 1):S9-14.
  • 2. Kimura K., Arakawa Y., Ohsuka S., et al. Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob Agents Chemother 1996; 40:1988-94.
  • 3. McLaughlin J.C., Barry A.L., Fuchs P.C., et al. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 33:223-30.
  • 4. Nomura S., Hanaki H., A. Nagayama. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. J Chemother 1997; 9:89-94.
  • 5. Rice L.B., Carias L.L., Etter L., Shlaes D.M. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob Agents Chemother 1993; 37:1061-64.
  • 6. Burgess D.S., Hall R.G. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2004; 49:41-6.
  • 7. Kang C.I., Pai H., Kim S.H., et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother 2004; 54:1130-3.
  • 8. Thomson K.S., Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
  • 9. Queenan A.M., Foleno B., Gownley C., et al. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42:269-75.
  • 10. Edelstein M., Edelstein I., Semchenkova D., Stratchounski L. The effect of large inoculaon in vitro activities of penicillin-inhibitor combinations and cefoperazone-sulbactam against ESBL-producing Escherichia coli and Klebsiella pneumoniae strains. (Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases), Prague, 2004. Abstr. P1723
  • 11. Procop G.W., Tuohy M.J., Wilson D.A., et al. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Clin Pathol 2003; 120:265-7.
  • 12. Spanu T., Luzzaro F., Perilli M., et al. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46:196-202.
  • 13. Winokur P.L., Eidelstain M.V., Stetsiouk O., et al. Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases. Clin Microbiol Infect 2000; 6:103-8.
  • 14. Paterson D.L., Mulazimoglu L., Casellas J.M., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
  • 15. Yu W.L., Jones R.N., Hollis R.J., et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40:4666-9.
  • 16. Graffunder E.M., Preston K.E., Evans A.M., Venezia R.A. Risk factors associated with extended-spectrum {beta}-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005$ 56:139-45.
  • 17. Sirot D., Champs C.De, Chanal C., et al. Translocation of antibiotic resistance determinants including an extended-spectrum beta-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 1991; 35:1576-81.
  • 18. Araque M., Rivera I. Simultaneous presence of blaTEM and blaSHV genes on a large conjugative plasmid carried by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Med Sci 2004; 327:118-22.
  • 19. Mammeri H., Van De L.M., Poirel L., et al. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49:71-6.
  • 20. Wang M., Sahm D.F., Jacoby G.A., Hooper D.C. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48:1295-9.
  • 21. Jones R.N., Pfaller M.A.. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9:708-12.
  • 22. Bouchillon S.K., Johnson B.M., Hoban D.J., et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004; 24:119-24.
  • 23. Nijssen S., Florijn A., Bonten M.J. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24:585-91.
  • 24. Edelstein M., Pimkin M., Palagin I., et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003; 47:3724-32.
  • 25. Методические указания МУК 4.2.1890-04. 2004. Определение чувствительности микроорганизмов к антибактериальным препаратам.
  • 26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 27. Mabilat C., S. Goussard. 1993. PCR detection and identification of genes for extended-spectrum β-lactamases, p. 553-562. In: Persing D.H., Smith T.F., Tenover F.C., White T.J. (eds.), Diagnostic molecular microbiology. Principles and Applications. American Society for Microbiology, Washington, DC.
  • 28. Edelstein M., Pimkin M., Dmitrachenko T., et al. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2004; 48:2808-15.
  • 29. Ekimov A., Edelstein M., Belousov E. A single-tube PCR with MGB Eclipse probes for detection of SHV-type extended-spectrum beta-lactamases (ESBLs). Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, 2004; Abstr. P944.
  • 30. Edelstein M., Ekimov A., Stratchounski L. Prevalence of mutations conferring extended-spectrum activity on SHV beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from Russian nationwide survey. Proceedings 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004. Abstr. C2-1331.
  • 31. Livermore D.M. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-84.
  • 32. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
  • 33. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
  • 34. Paterson D.L., Ko W.C., Von Gottberg A., et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7.
  • 35. Szabo D., Mathe A., Filetoth Z., et al. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45:1287-91.
  • 36. Paterson D.L., Ko W.C., Von Gottberg A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
  • 37. Ambrose P.G., Bhavnani S.M., Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47:1643-6.
  • 38. Maglio D., Ong C., Banevicius M.A., et al. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48:1941-7.
  • 39. Ромашов О. М., Яковлев С.В., Сидоренко С.В., Березин А.Г. Эффективность цефепима при лечении нозокомиальных инфекций, вызванных энтеробактериями–продуцентами бета-лактамаз расширенного спектра. Инфекции и антимикробная терапия 2003; 5.
  • 40. Yakovlev S., Romashov O., Sidorenko S.V., Eryomina L. Impact of extended-spectrum beta-lactamases produced by Gram-negative bacteria on efficacy of cephalosporins and quinolones. Proceedings 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, 2005: Abstr. P437.
  • 41. Yu W.L., Pfaller M.A., Winokur P.L., Jones R.N. Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae. Taiwan. Emerg Infect Dis 2002; 8:522-4.
  • 42. Bonnet R., Sampaio J.L., Labia R., et al. A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother 2000; 44:1936-42.
  • 43. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48:1-14.
  • 44. Perilli M., Ettorre D., Segatore B., et al. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli. FEMS Microbiol Lett 2004; 241:229-32.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared